A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
Official title: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P29/00 (Non-central analgesic, antipyretic or antiinflammatory agents) appears on 48,693 US grants and 70,953 published applications in this corpus.
Search patents in A61P- Granted patents
- 48,693
- Published applications
- 70,953
- Assignees
- 14,504
- Inventors
- 90,883
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 53 | 0 |
| 1977 | 59 | 0 |
| 1978 | 85 | 0 |
| 1979 | 56 | 0 |
| 1980 | 75 | 0 |
| 1981 | 112 | 0 |
| 1982 | 89 | 0 |
| 1983 | 70 | 0 |
| 1984 | 89 | 0 |
| 1985 | 120 | 0 |
| 1986 | 97 | 0 |
| 1987 | 113 | 0 |
| 1988 | 122 | 0 |
| 1989 | 183 | 0 |
| 1990 | 190 | 0 |
| 1991 | 189 | 0 |
| 1992 | 212 | 0 |
| 1993 | 158 | 0 |
| 1994 | 236 | 0 |
| 1995 | 285 | 0 |
| 1996 | 335 | 0 |
| 1997 | 507 | 0 |
| 1998 | 637 | 0 |
| 1999 | 712 | 0 |
| 2000 | 719 | 0 |
| 2001 | 855 | 230 |
| 2002 | 981 | 1341 |
| 2003 | 1027 | 2308 |
| 2004 | 844 | 2863 |
| 2005 | 839 | 2833 |
| 2006 | 1187 | 2906 |
| 2007 | 1227 | 3096 |
| 2008 | 1315 | 3565 |
| 2009 | 1596 | 4107 |
| 2010 | 2204 | 4653 |
| 2011 | 2295 | 4665 |
| 2012 | 2847 | 4615 |
| 2013 | 3158 | 3650 |
| 2014 | 3235 | 3629 |
| 2015 | 2813 | 3369 |
| 2016 | 2410 | 3236 |
| 2017 | 2520 | 2987 |
| 2018 | 2159 | 2707 |
| 2019 | 2040 | 2520 |
| 2020 | 1733 | 2210 |
| 2021 | 1483 | 1971 |
| 2022 | 1148 | 1777 |
| 2023 | 935 | 1779 |
| 2024 | 906 | 1640 |
| 2025 | 940 | 1399 |
| 2026 | 493 | 897 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions comprising curcuminoids for use in the treatment of muscle soreness6 Oct 2026US 12,751,932 B2Givaudan SA
- Anti-inflammatory agent and method of producing extracellular vesicle having anti-inflammatory action6 Oct 2026US 12,751,975 B2Fujifilm Wako Pure Chemical Corporation
- Bifidobacterium longum CCFM1206 capable of producing sulforaphane and relieving inflammation6 Oct 2026US 12,751,980 B2Jiangnan University
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Topical composition for treatment of pain and symptoms associated with rhinosinusitis, method of making, and method of use29 Sep 2026US 12,746,256 B2Three Fifths, LLC
- Identification of mechanosensing regulators in plasmacytoid dendritic cells8 Oct 2026US 2026/0306507 A1New York Society for the Relief of Theruptured and Crippled, Maintaining the Hospital Special --
- Composition, methods and uses8 Oct 2026US 2026/0306509 A14E Therapeutics, Inc.
- Cannabinoid-based formulation8 Oct 2026US 2026/0306516 A1
- Combination therapy glucocorticoids and ginsenoside8 Oct 2026US 2026/0306525 A1Fytagoras
- Composition including propionibacterium freudenreichii mj2 strainderived extracellular vesicles or chaperonin protein as active ingredient for prevention, alleviation, or treatment of rheumatoid arthritis8 Oct 2026US 2026/0306557 A1Korea University Research and Business Foundation
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Drug depot implant designs1,379US 7,727,954 B2Warsaw Orthopedic, Inc. · 2010